TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04190004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressins
Description: 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Study: NCT03973905

Intervention type: OTHER
Intervention: Not applicable / dataset analysis
Description: Not applicable / dataset analysis

Intervention type: OTHER
Intervention: Not applicable / dataset analysis
Description: Not applicable / dataset analysis
Study: NCT02048033

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular endoscopy + endogastric suturing
Description: Patients will get the usual endoscopy used for diagnosis. In addition, they will receive an endoscopic surgery using the APOLLO Endosuregery technique. The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Regular endoscopy
Description: Patients will get the usual endoscopy used for diagnosis.
Study: NCT01628003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI
Description: Brain MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Physical examination Neuropsychological testing Questionnaires

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Physical examination Neuropsychological testing Questionnaires
Study: NCT01884571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 1-5 mg PO, twice a day (BID) days 2-180.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
Study: NCT01078051

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher, xience, Endeavor, Taxus
Description: all species of drug-eluting stent implantation
Study: NCT00763945

Intervention type: OTHER
Intervention: data collection
Description: The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
Study: NCT01078051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal medical therapy
Description: optimal medical therapy
Study: NCT02301286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Study: NCT02698904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Relaxation Technique

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Documentary Movie
Study: NCT02137187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AV junction ablation
Description: AV junction ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized drug therapy
Description: Optimized drug therapy for heart failure and atrial fibrillation rate control
Study: NCT02301286

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acetylsalicylic acid
Study: NCT02137187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized drug therapy
Description: Optimized drug therapy for heart failure and atrial fibrillation rate control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD
Description: Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD
Description: Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
Study: NCT00842101

Intervention type: DEVICE
Intervention: Quick Pressure Monitor
Description: The monitor measures actively the actual pressure inside the compartment affected.
Study: NCT02803996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
Study: NCT03445221

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IV Immunonutrition
Description: patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet
Description: patients will continue preoperative oral conventional diet.
Study: NCT02126007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep and Rhythm Intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Modifications
Study: NCT03610776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portion control plate
Description: Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional plate
Description: Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
Study: NCT02435706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless immediate implant placement
Description: Experimental group: No elevation of flap prior to immediate implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap assisted immediate implant placement
Description: Control group: Flap will be elevated prior to immediate implant placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant and temporary crown
Description: Both groups receive this intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant and temporary crown
Description: Both groups receive this intervention
Study: NCT03930992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colaren in HIV positive
Description: 1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment in HIV positive
Description: 2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colaren in HIV negative
Description: 3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment in HIV negative
Description: 4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Study: NCT02068417

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: shock waves
Description: extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock waves
Description: extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
Study: NCT04556422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 15 minutes of aerobic exercise using stationary bicycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauna bathing
Description: Passive heat exposure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sauna bathing
Description: Passive heat exposure
Study: NCT02694952

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FAV-Africa
Description: Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EchiTabPlus-ICP
Description: Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
Study: NCT02772900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot-based nutritional gel
Description: 100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
Study: NCT04835025

Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitor
Description: In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
Study: NCT02507583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
Study: NCT02323230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose cyclophosphamide will be taken by mouth
Study: NCT01978587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Study: NCT04273646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 4 times of UC-MSCs(0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
Study: NCT02772900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
Study: NCT00024011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00464659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective CPAP
Description: Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
Study: NCT03459053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBART
Description: Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
Study: NCT04356079

Intervention type: DIAGNOSTIC_TEST
Intervention: International Headache Society Test
Description: Thorough History of Patients and families

Intervention type: DIAGNOSTIC_TEST
Intervention: International Headache Society Test
Description: Thorough History of Patients and families
Study: NCT05919303

Intervention type: RADIATION
Intervention: CT Scan
Description: CT scan study of abdomen
Study: NCT01930851

Intervention type: PROCEDURE
Intervention: Gastric bypass operation
Study: NCT01986855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 5 mg
Description: Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Description: Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 10 mg
Description: Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10 mg
Description: Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
Study: NCT01221532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHHE Peridischarge Intervention
Description: Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~1. a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~2. two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~3. the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care.
Study: NCT03745937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
Study: NCT02659709

Intervention type: DEVICE
Intervention: Interest in medical education through social media
Description: Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
Study: NCT02428881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
Study: NCT04571775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Qi-Shield user group
Description: real device Qi-Shield (treatment)
Study: NCT01045057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puncture Set and Flexible Protector
Description: The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
Study: NCT04139486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined EMBOTRAP II or III and Contact Aspiration
Description: refer to title

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Aspiration alone
Description: refer to title
Study: NCT04246723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
Study: NCT02409407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol , Prostaglandins E1 analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol , Prostaglandins E1 analogue
Study: NCT00598234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib (Celebrex)
Description: The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib (Celebrex)
Description: The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
Study: NCT04571775

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Qi-Shield user group
Description: sham device (placebo)
Study: NCT00424502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1g iv on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg po/week
Study: NCT02680028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: targon pft nail
Description: 220 mm vs 175mm nail

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: targon pft nail
Description: 220 mm vs 175mm nail
Study: NCT00213759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextrose 5%
Description: The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
Study: NCT03346590

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Energy metabolism of patients suffering from RA
Description: Energy metabolism of patients suffering from RA
Study: NCT00225251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion XL
Description: Antidepressant medication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01838031

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thyroid screening
Description: The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
Study: NCT03279328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Steroid Ointment
Description: Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline
Description: Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
Study: NCT04246723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle.
Study: NCT04477057

Intervention type: DRUG
Group type: OTHER
Intervention: HS-10241
Description: HS-10241 is a tablet in the form of 100 mg, oral, once daily.
Study: NCT01177969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list
Description: A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
Study: NCT02093910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialotetrahexosylganglioside
Study: NCT04250597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNX102
Description: Dose Escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNX102
Description: Dose Escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNX102
Description: Expansion Phase